Emerging treatments

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print]. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood Cancer J. 2015 Aug 14;4:e338. doi: 10.1038/bcj.2015.60. Panobinostat: the small molecule metalloenzyme inhibitor with marvelous anticancer activity. Ganai SA. Curr Top Med…

Biology and genetics

A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias. Lionetti M et al. Oncotarget. 2015 Jul 20. [Epub ahead of print]. The natural compound forskolin synergizes with dexamethasone to induce cell death in myeloma cells via BIM. Follin-Arbelet V et al. Sci Rep. 2015 Aug 26;5:13001. doi: 10.1038/srep13001. Notch signaling deregulation in multiple myeloma: A rational molecular target. Colombo M et…

General

Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents. Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print]. IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature. Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5.…

Complications of myeloma and its treatments

Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Gu ZH et al. Int J Clin Exp Med. 2015 Jun 15;8(6):10105-10108. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Vincent L et al. Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. Hematopoietic cell transplantation in patients with medication-related osteonecrosis of the jaws. Mawardi…

Current treatments

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print]. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis. Minoia C et al. Bone Marrow Transplant. 2015 Aug…

Diagnostic tests and prognostic indicators

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ayuk F et al. Ann Hematol. 2015 Jul 24. [Epub ahead of print]. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Oral A et al. Clin Nucl Med. 2015 Jul 22. [Epub ahead of print]. Tumor associated macrophages (TAMs) and extraczellular…

Related conditions

Neoplastic and Non-Neoplastic Complications of Solid Organ Transplantation in Patients with Preexisting Monoclonal Gammopathy of Undetermined Significance (MGUS). Goebel TE et al. Clin Transplant. 2015 Jul 21. doi: 10.1111/ctr.12595. [Epub ahead of print]. Kidney involvement in Crow-Fukase syndrome. Zouaghi K et al. Saudi J Kidney Dis Transpl. 2015 Jul-Aug;26(4):751-6. doi: 10.4103/1319-2442.160201. Bortezomib produces high hematological response rates with prolonged renal survival…

Emerging treatments

T-cell receptor therapy shows promise in multiple myeloma. Bagcchi S. Lancet Oncol. 2015 Jul 23. pii: S1470-2045(15)00191-6. doi: 10.1016/S1470-2045(15)00191-6. [Epub ahead of print]. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Rapoport AP et al. Nat Med. 2015 Jul 20. doi: 10.1038/nm.3910. [Epub ahead of print]. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple…